The functional significance of nuclear receptor acetylation

Steroids

Volumn 72, Issue 2, 2007, Pages 221-230

  Popov, Vladimir M ^a   Wang, Chenguang ^a   Shirley, L Andrew ^a   Rosenberg, Anne ^a   Li, Shengwen ^a   Nevalainen, Marja ^a   Fu, Maofu ^a   Pestell, Richard G ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acetylation; Breast cancer; Prostate cancer; SIRT1

Indexed keywords

ACETIC ACID DERIVATIVE; AMINE; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; LYSINE; LYSINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P300;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL METABOLISM; COLON CANCER; DEACETYLATION; ENZYME MECHANISM; GENETIC CONSERVATION; HORMONAL REGULATION; HUMAN; NONHUMAN; PHYLOGENY; PROSTATE CANCER; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; THYROID CANCER; TRANSCRIPTION REGULATION; UBIQUITINATION;

ACETYLATION; ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 33847014864     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2006.12.001     Document Type: Article

References (58)

1. Waddington C.H. Organisers and genes (1940), Cambridge University Press
2. Neumeister P., Albanese C., Balent B., Greally J., and Pestell R. Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol 34 (2002) 1475
3. Fu M., Wang C., Wang J., Zafonte B.T., Lisanti M.P., and Pestell R.G. Acetylation in hormone signaling and the cell cycle. Cytokine Growth Factor Rev 13 (2002) 259-276
4. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (2003) 737-749
5. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273 (2000) 793-798
6. Yang T., Fu M., Pestell R., and Sauve A.A. SIRT1 and endocrine signaling. Trends Endocrinol Metab 17 (2006) 186-191
7. Sauve A.A., Celic I., Avalos J., Deng H., Boeke J.D., and Schramm V.L. Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. Biochemistry 40 (2001) 15456-15463
8. Kaeberlein M., McVey M., and Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13 (1999) 2570-2580
9. Tissenbaum H.A., and Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410 (2001) 227-230
10. Tissenbaum H.A., and Guarente L. Model organisms as a guide to mammalian aging. Dev Cell 2 (2002) 9-19
11. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124 (2006) 315-329
12. Rodgers J.T., and Puigserver P. Certainly can't live without this: SIRT6. Cell Metab 3 (2006) 77-78
13. Bouras T., Fu M., Sauve A.A., Wang F., Quong A.A., Perkins N.D., et al. SIRT1 deacetylation and repression of P300 involves lysine residues 1020/1024 within the cell-cycle regulatory domain 1. J Biol Chem 280 (2005) 10264-10276
14. Goodman R.H., and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 14 (2000) 1553-1577
15. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., et al. p300 transcriptional repression is mediated by SUMO modification. Mol Cell 11 (2003) 1043-1054
16. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107 (2001) 137-148
17. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., et al. A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001) 149-159
18. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004) 2011-2015
19. Fulco M., Schiltz R.L., Iezzi S., King M.T., Zhao P., Kashiwaya Y., et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 12 (2003) 51-62
20. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116 (2004) 551-563
21. 168, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. EMBO J 20 (2001) 1353-1362
22. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8 (2001) 1243-1254
23. Fu M., Sauve A.A., Liu M., Jiao X., Zhang X., Powell M., et al. Hormonal control of androgen receptor function through SIRT1. Mol Biol Cell 26 (2006) 8122-8135
24. Dickson R.B., Pestell R.G., and Lippman M.E. In: De Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Molecular biology of breast cancer. Cancer: principles and practice of oncology. 7th ed (2005) 1399-1414
25. Pike M.C., Spicer D.V., Dahmoush L., and Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15 (1993) 17-35
26. Rosen E.M., Fan S., Pestell R.G., and Goldberg I.D. BRCA1 gene in breast cancer. J Cell Physiol 196 (2003) 19-41
27. Giacinti L., Claudio P.P., Lopez M., and Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11 (2006) 1-8
28. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276 (2001) 18375-18383
29. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60 (2000) 4026-4029
30. Kim M.Y., Woo E.M., Chong Y.T.E., Homenko D.R., and Kraus W.L. Acetylation of estrogen receptor a by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activies of the receptor. Mol Endocrinol 20 (2006) 1479-1493
31. Knights C.D., Catania J., Giovanni S.D., Muratoglu S., Perez R., Swartzbeck A., et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173 (2006) 533-544
32. Le Corre L., Chalabi N., Delort L., Bignon Y.J., and Bernard-Gallon D.J. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49 (2005) 462-471
33. Amanatullah D.F., Reutens B., Zafonte B., Fu M., Mani S., and Pestell R. Cell-cycle dysregulation in prostate cancer. Front Biosci 1 (2000) 372-390
34. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics, 2003. CA Cancer J Clin 53 (2003) 5-26
35. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275 (2000) 20853-20860
36. Gong J., Zhu J., Goodman O.B., Pestell R.G., Schlegel P.N., Nanus D.M., et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 25 (2006) 2011-2021
37. Fu M., Rao M., Wu K., Wang C., Zhang X., Hessien M., et al. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem 279 (2004) 29436-29449
38. Fu M., Wang C., Wang J., Sakamaki T., Zhang X., Yeung Y.-G., et al. The androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and transrepression function. Mol Cell Biol 22 (2002) 3373-3388
39. Fu M., Wang C., Wang J., Sakamaki T., Di Vizio D., Zhang X., et al. Acetylation of the androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23 (2003) 8563-8575
40. Thomas M., Dadgar N., Aphale A., Harrell J.M., Kunkel R., Pratt W.B., et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem 279 (2004) 8389-8395
41. Fu M., Wang C., Rao M., Wu X., Bouras T., Zhang X., et al. Cyclin D1 represses p300 transactivation through a CDK-independent mechanism. J Biol Chem 28 (2005) 29728-29742
42. Fu M., Liu M., Sauve A.A., Jiao X., Zhang X., Wu X., et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26 (2006) 8122-8135
43. Seligson D.B., Horvath S., Shi T., Yu H., Tse S., Grunstein M., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
44. Baron A., Migita T., Tang D., and Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 91 (2004) 47-53
45. Rossi S., Graner E., Febbo P., Weinstein L., Bhattacharya N., Onody T., et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1 (2003) 707-715
46. Altenberg B., and Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 (2004) 1014-1020
47. Girnun G.D., and Spiegelman B.M. PPARgamma ligands: taking Ppart in chemoprevention. Gastroenterology 124 (2003) 564-567
48. Wang C., Pattabiraman N., Zhou J.N., Fu M., Sakamaki T., Albanese C., et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 23 (2003) 6159-6173
49. Hulit J., Wang C., Li Z., Albanese C., Rao M., Di Vizio D., et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 24 (2004) 7598-7611
50. Ohta K., Endo T., Haraguchi K., Hershman J.M., and Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 2170-2177
51. Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., et al. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 (2006) 4463-4475
52. Keshamouni V.G., Reddy R.C., Arenberg D.A., Joel B., Thannickal V.J., Kalemkerian G.P., et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23 (2004) 100-108
53. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18 (2004) 528-540
54. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
55. Leader J.E., Wang C., Fu M., and Pestell R.G. Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol 72 (2006) 1589-1596
56. Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284 (1999) 1354-1356
57. Wang C., Fan S., Li Z., Fu M., Rao M., Ma Y., et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 65 (2005) 6557-6567
58. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer 2 (2002) 777-785